September 6, 2007 - While few complications were found last year with implantable cardioverter defibrillators (ICDs), 15 percent of implanting physicians had no formal training with the medical procedure, according to first-year data from the National ICD Registry.

September 6, 2007 – The New England Journal of Medicine published the first study to demonstrate a clear superiority of newer forms of dual chamber pacing for sinus node disease versus older pacemaker technology.

September 5, 2007 – According to Boston Scientific Corp., results from the TAXUS WOMAN study, a gender specific analysis of the TAXUS II, IV, V and VI trials assessing the efficacy data of the TAXUS paclitaxel-eluting coronary stent in women undergoing coronary revascularization, found paclitaxel-eluting stents to have similar clinical outcomes in women and men, despite the higher risk profile in women patients.

September 6, 2007 - Cleveland Clinic will host its fifth annual Medical Innovation Summit, an international gathering of healthcare, business and media leaders to examine trends in medical innovation and cardiovascular technologies, Oct. 1-3.

September 6, 2007 – Boston Scientific Corp. announced at the ESC 2007 conference in Vienna, Austria, that results from the five-year TAXUS II clinical trial found that the TAXUS paclitaxel-eluting stent showed no additional stent thrombosis between years four and five, while the bare-metal control experienced one stent thrombosis during this same period.

The results from the study mark the third consecutive year of TAXUS II follow-up with no stent thrombosis seen in the TAXUS stent patient group.

Siemens Automation and Drives (A&D) has added a 1MP color display to its portfolio of medical monitors. The SCD 19110 offers high luminance of up to 300 cd/m2 (candelas per square meter) and an outstanding contrast ratio of 1000:1.

GE Healthcare Medical Diagnostics’ VISIPAQUE is reportedly the only isosmolar contrast medium (IOCM) available in the U.S. With an osmolality equal to that of blood, VISIPAQUE was designed for patient safety and comfort and is also formulated with sodium and calcium in a ratio equivalent to blood.

Guerbet’s flagship X-ray contrast agent, Oxilan (ioxilan) injection, is a contrast agent that is a nonionic, low-viscous and low-osmolar monomer.
The 2007 Frost & Sullivan Product Quality Leadership Award is presented to Guerbet for the recognized quality of its contrast media products in the North American Contrast Media Market.
Although there are possible side effects that can arise following injection of X-ray contrast media, Oxilan has had reportedly favorable results with usage feedback, indicating it is a safe product.

GE Healthcare has released the latest version of Centricity Enterprise, an intelligent and integrated software suite of clinical and financial applications that is designed to improve patient care and increase collaboration between clinicians, providing a better overall healthcare environment.

Siemens Medical Solutions Ultrasound Division’s syngo Arterial Health Package (AHP) application for cardiovascular risk assessment provides semi-automated quantification tools for users that help to assess the cardiovascular risk potential of patients using the concept of “vascular age.”

The syngo AHP is available on the ACUSON Sequoia C512 echocardiography platform and the new ACUSON X300 all-purpose ultrasound system.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now